Thomas J. Salentine Jr.
CIK: 0002037899
Thomas J. Salentine Jr.'s purchase track record
Thomas J. Salentine Jr. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/27/2024 | GRDN | $500K | +19.5% | +13.5% | -2.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GRDN | ▲ Buy | Option Exercise | 6,100,175 | — | 9/27/2026 | View on chart |
| GRDN | ▲ Buy | Option Exercise | 6,100,175 | — | 3/28/2026 | View on chart |
| GRDN | ▼ Sell | Open Market | 3,570,677 | $106.0M | 3/20/2026 | View on chart |
| GRDN | ▲ Buy | Option Exercise | 6,100,176 | — | 9/27/2025 | View on chart |
| GRDN | ▼ Sell | Open Market | 651,454 | $13.1M | 5/28/2025 | View on chart |
| GRDN | ▼ Sell | Open Market | 3,508,905 | $70.7M | 5/27/2025 | View on chart |
| GRDN | ▲ Buy | Option Exercise | 6,100,176 | — | 3/28/2025 | View on chart |
| GRDN | ▲ Buy | Open Market | 35,714 | $500K | 9/27/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Guardian Pharmacy Services Q2 2026 Earnings Call Highlights
Guardian Pharmacy Services held its Q2 2026 earnings conference call, reviewing the quarter’s financial results and outlook. Management addressed performance metrics and future expectations, offering insight for investors. The discussion comes as the stock trades near its recent support level of $40.33, with an RSI around 40, indicating modest momentum.
Guardian Pharmacy Services Q2 2026 Earnings Call Highlights. Guardian Pharmacy Services held its Q2 2026 earnings conference call, reviewing the quarter’s financial results and outlook. Management addressed performance metrics and future expectations, offering insight for investors. The discussion comes as the stock trades near its recent support level of $40.33, with an RSI around 40, indicating modest momentum.